⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101885 | 0.92 | — | — | |
| SCHEMBL307585 | 0.80 | — | — | |
| SCHEMBL7420591 | 0.67 | — | — | |
| SCHEMBL7170234 | 0.64 | — | — | |
| SCHEMBL17477583 | 0.64 | ALDH1A1 (0.58) | — | |
| SCHEMBL17477579 | 0.64 | ALDH1A1 (0.58) | — | |
| SCHEMBL5160937 | 0.63 | — | — | |
| SCHEMBL18839391 | 0.62 | — | — | |
| SCHEMBL6027741 | 0.61 | ALDH1A1 (0.47) | — | |
| SCHEMBL6053208 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077803-A1 | Uses Of NK Receptor Antagonists | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | claimed |
| US-20110282053-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | claimed |
| US-8008479-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | claimed |
| EP-2010498-B1 | SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20090137797-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-05-28 | — | — | US | claimed |
| EP-2010498-A1 | SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS | Novartis AG (CH) | 2009-01-07 | — | — | EP | claimed |
| US-20070293473-A1 | Administering (4R) [N'-methyl-N'-(3,5-bistrifluoromethyl-benzoyl)-amino]-5-(1-methyl-indol-3-yl)-pent-2-enoic acid N [(R)-epsilon-caprolactam-3-yl]-amide; constipation, diarrhoea, functional dyspepsia, gastro-oesophageal reflux disease, functional abdominal bloating | FOZARD JOHN R | 2007-12-20 | — | — | US | claimed |
| WO-2007118651-A1 | SYNTHESIS OF ACYLAMINOALKENYLENE AMIDES USEFUL AS SUBSTANCE P ANTAGONISTS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | claimed |
| US-20070149504-A1 | Use of neurokinin antagonists in the treatment of urinary incontinence | NOVARTIS AG (CH) | 2007-06-28 | — | — | US | claimed |
| EP-1686985-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| US-20050203164-A1 | Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera | FOZARD JOHN R (FR) | 2005-09-15 | — | — | US | claimed |
| WO-2005039563-A2 | USE OF NEUROKININ ANTAGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | claimed |
| EP-1476167-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | Novartis AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2004037266-A1 | COMPOUNDS FOR THE TREATMENT OF COUGH | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | claimed |
| WO-2003066062-A1 | USE OF ACYLAMINOALKENYLENE-AMIDE DERIVATIVES IN FUNCTIONAL MOTILITY DISORDERS OF THE VISCERA | NOVARTIS AG (CH) | 2003-08-14 | — | — | WO | claimed |
| EP-0923550-B1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6319917-B1 | NEUROGENIC INFLAMMATION AND TACHYKININ BRONCHOCONSTRICTION INHIBITORS | NOVARTIS AG (CH) | 2001-11-20 | — | — | US | claimed |
| WO-2001085696-A1 | BUTENOIC ACIDS DERIVATIVES AND THEIR USE IN THE TREATMENT OF RHINITIS | NOVARTIS AG (CH) | 2001-11-15 | — | — | WO | claimed |
| EP-0923550-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | Novartis AG (CH) | 1999-06-23 | — | — | EP | claimed |
| WO-1998007694-A1 | ACYLAMINOALKENYLENE-AMIDE DERIVATIVES AS NK1 AND NK2 ANTAGONISTS | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | claimed |